Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide 50 mg - bicalutamide tablets 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily are not approved for use alone or with other treatments [see clinical studies (14.2) ]. bicalutamide tablets are contraindicated in: - hypersensitivity bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide tablets have no indication for women, and should not be used in this population. - pregnancy bicalutamide tablets can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for use in f